当前位置: X-MOL 学术Leukemia › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.
Leukemia ( IF 12.8 ) Pub Date : 2019-12-03 , DOI: 10.1038/s41375-019-0645-z
Anne Sophie Kubasch 1, 2, 3 , Freya Schulze 2, 3, 4 , Aristoteles Giagounidis 2, 3, 5 , Katharina S Götze 2, 3, 6 , Jan Krönke 2, 3, 7 , Katja Sockel 2, 3, 4 , Jan Moritz Middeke 2, 3, 4 , Fatiha Chermat 3, 8 , Silke Gloaguen 2, 3 , Martin Puttrich 3, 9 , Carmen Weigt 3, 9 , Doreen William 10, 11 , Pierre Fenaux 3, 8, 12 , Richard F Schlenk 3, 11, 13 , Christian Thiede 3, 4 , Sebastian Stasik 3, 4 , Anna Mies 3, 4 , Lionel Adès 3, 8, 12 , Uta Oelschlägel 2, 3, 4 , Uwe Platzbecker 1, 2, 3
Affiliation  



中文翻译:

单药他拉库珠单抗在低甲基化药物失败的老年高危MDS或AML患者中显示出有限的疗效,但毒性显着。

更新日期:2019-12-04
down
wechat
bug